CLDN6 and gastric cancer: DS-9606a revealed preliminary partial responses in four of 53 cancer patients (Patel et al., 2024), whereas QLS5132, which has a wide therapeutic window, is expected to exhibit superior efficacy and safety profiles in patients with CLDN6-positive ovarian cancers, gastric cancers, NSCLCs and other cancers (Huang Y et al., 2025).